---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-045527"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:27:59.456969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track

## Summary
- Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.
- Cash, cash equivalents and restricted cash increased to $33.0M from $15.8M at Sep 30, 2025.
- Operating loss from continuing operations improved to $5.4M from $10.2M.
- Phase 2b PLATEAU trial of enobosarm+semaglutide in obesity to start Q1 2026; interim analysis Q1 2027.
- R&D spend fell to $1.3M from $5.7M; G&A to $4.1M from $5.2M.

## SEC filing metadata
- accession: 0001193125-26-045527
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/0001193125-26-045527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-045527
- JSON: https://secwatch.observer/filing/0001193125-26-045527.json
- Plain text: https://secwatch.observer/filing/0001193125-26-045527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.